R. Déporte-Féty

570 total citations
12 papers, 434 citations indexed

About

R. Déporte-Féty is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, R. Déporte-Féty has authored 12 papers receiving a total of 434 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 3 papers in Molecular Biology and 2 papers in Pathology and Forensic Medicine. Recurrent topics in R. Déporte-Féty's work include Colorectal Cancer Treatments and Studies (5 papers), Cancer Treatment and Pharmacology (5 papers) and Pancreatic and Hepatic Oncology Research (2 papers). R. Déporte-Féty is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Cancer Treatment and Pharmacology (5 papers) and Pancreatic and Hepatic Oncology Research (2 papers). R. Déporte-Féty collaborates with scholars based in France, Germany and United States. R. Déporte-Féty's co-authors include G. Milano, N. Renée, Muriel Barberi‐Heyob, Valérie Pierrefite‐Carle, M C Etienne, Mario Campone, L. Campion, Stéphane Minvielle, Delphine Loussouarn and Catherine Guérin‐Charbonnel and has published in prestigious journals such as British Journal of Cancer, Annals of Oncology and British Journal of Clinical Pharmacology.

In The Last Decade

R. Déporte-Féty

12 papers receiving 425 citations

Peers

Countries citing papers authored by R. Déporte-Féty

Since Specialization

Citations

This map shows the geographic impact of R. Déporte-Féty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Déporte-Féty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Déporte-Féty more than expected).

Fields of papers citing papers by R. Déporte-Féty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Déporte-Féty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Déporte-Féty. The network helps show where R. Déporte-Féty may publish in the future.

Co-authorship network of co-authors of R. Déporte-Féty

This figure shows the co-authorship network connecting the top 25 collaborators of R. Déporte-Féty. A scholar is included among the top collaborators of R. Déporte-Féty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Déporte-Féty. R. Déporte-Féty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Relationship between 5‐fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy 2007 ·British Journal of Clinical Pharmacology ·Maud Bénéton, S. Chapet, Hélène Blasco, Bruno Giraudeau, M. Boisdron‐Celle, R. Déporte-Féty, Fabrice Denis, (unknown), G. Calais, Chantal Le Guellec	6
2	Surface‐enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node‐negative breast cancer tumors 2006 ·PROTEOMICS ·Gabriel Ricolleau, Catherine Guérin‐Charbonnel, Laurence Lodé, Delphine Loussouarn, Marie‐Pierre Joalland, Ralf Bogumil, (unknown), Stéphane Minvielle, Mario Campone, R. Déporte-Féty, L. Campion, Pascal Jézéquel	73
3	Vinorelbine/docetaxel combination treatment of metastatic breast cancer: a phase I study 2006 ·Cancer Chemotherapy and Pharmacology ·Jacques Bonneterre, M. Campone, (unknown), Maria Błasińska-Morawiec, R. Déporte-Féty, Étienne Chatelut, F. Léger, (unknown), (unknown), (unknown)	7
4	Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer 2004 ·Cancer Chemotherapy and Pharmacology ·R. Déporte-Féty, Nicolas Simon, P. Fumoleau, Mario Campone, Pierre Kerbrat, Jacques Bonneterre, P. Fargeot, Saı̈k Urien	9
5	Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer 2003 ·Cancer Chemotherapy and Pharmacology ·Saı̈k Urien, P. Fumoleau, Mario Campone, Pierre Kerbrat, Jacques Bonneterre, P. Fargeot, R. Déporte-Féty	9
6	Individual adaptive dosing of topotecan in ovarian cancer. 2002 ·PubMed ·(unknown), Stéphane Culine, Brigitte Laguerre, Frédéric Pinguet, François Lokiec, Nicolas Albin, A Goupil, R. Déporte-Féty, R. Bugat, Pierre Canal, Étienne Chatelut	19
7	Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer 2001 ·Annals of Oncology ·Mario Campone, P. Fumoleau, Valérie Delecroix, R. Déporte-Féty, G. Perrocheau, Laurent Vernillet, (unknown), J.P. Louboutin, Marie-Christine Bissery, A. Riva, N. Azli	20
8	High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: application to measurement of dihydropyrimidine dehydrogenase activity 2001 ·Journal of Chromatography B Biomedical Sciences and Applications ·R. Déporte-Féty, (unknown), (unknown), A. Moreau, L. Campion, (unknown), N. Renée, G. Milano	20
9	Population pharmacokinetics of topotecan: intraindividual variability in total drug 2000 ·Cancer Chemotherapy and Pharmacology ·(unknown), (unknown), François Lokiec, Frédéric Pinguet, Stéphane Culine, R. Déporte-Féty, Nicolas Albin, Brigitte Laguerre, A Goupil, R. Bugat, Pierre Canal, Étienne Chatelut	30
10	Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer 2000 ·Cancer Immunology Immunotherapy ·Jean‐Yves Douillard, Jaafar Bennouna, Fabienne Vavasseur, R. Déporte-Féty, (unknown), (unknown), Khaled Méflah	26
11	Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity 1999 ·British Journal of Cancer ·G. Milano, M C Etienne, Valérie Pierrefite‐Carle, Muriel Barberi‐Heyob, R. Déporte-Féty, N. Renée	213
12	UFT plus oral calcium folinate/vinorelbine for advanced breast cancer. 1999 ·PubMed ·P. Fumoleau, R. Déporte-Féty, Pierre Kerbrat, Brigitte Laguerre	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact